Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2026)

C4 Therapeutics has reported Change in Accured Expenses over the past 8 years, most recently at -$3.5 million for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 47.67% year-over-year to -$3.5 million; the TTM value through Mar 2026 reached -$2.8 million, down 750.6%, while the annual FY2025 figure was -$6.0 million, 377.43% down from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$3.5 million at C4 Therapeutics, down from $2.1 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $5.2 million in Q4 2023 and troughed at -$7.7 million in Q1 2024.
  • A 5-year average of -$261117.6 and a median of $537000.0 in 2023 define the central range for Change in Accured Expenses.
  • On a YoY basis, Change in Accured Expenses climbed as much as 669.17% in 2024 and fell as far as 426.07% in 2024.
  • Year by year, Change in Accured Expenses stood at $2.7 million in 2022, then skyrocketed by 92.5% to $5.2 million in 2023, then decreased by 23.29% to $4.0 million in 2024, then tumbled by 47.95% to $2.1 million in 2025, then crashed by 270.23% to -$3.5 million in 2026.
  • Business Quant data shows Change in Accured Expenses for CCCC at -$3.5 million in Q1 2026, $2.1 million in Q4 2025, and -$2.0 million in Q3 2025.